The European Medicines Agency has said no to approving a new drug for Alzheimer’s disease in the EU.
Aducanumab does not appear to be effective at treating adults with early-stage symptoms, the EMA said.
Alzheimer’s charities say they are disappointed by the decision because thousands of people are left with no treatment options.
The drug – the first new treatment for 20 years – was controversially approved in the US in June.
At the time, many scientists said there was little evidence from trials of it being of benefit despite it targeting amyloid – a protein that forms abnormal clumps in the brains of people with Alzheimer’s.
Biogen, the manufacturer of the drug, can ask for the EMA’s decision to be re-examined within the next two weeks.
- Indonesia issues tsunami warning after 7.5 magnitude earthquake hits region – National
- Mutant Gene Stops At-Risk People From Getting Alzheimer’s
- Holocaust Memorial Day: Portraits of last remaining UK survivors unveiled
- Finland reportedly moving toward buy of F-35 in $11B tender
- Covid: No new measures in England but we rule nothing out, says PM